Suppression of diabetic retinopathy with angiopoietin-1

American Journal of Pathology

Volumn 160, Issue 5, 2002, Pages 1683-1693

  Joussen, Antonia M ^a,b,c   Poulaki, Vassiliki ^a,b   Tsujikawa, Akitaka ^a,b   Qin, Wenying ^a,b   Qaum, Tamim ^a,b   Xu, Qingwen ^a,b   Moromizato, Yasufumi ^a,b   Bursell, Sven Erik ^d   Wiegand, Stanley J ^e   Rudge, John ^e   Ioffe, Ella ^e   Yancopoulos, George D ^e   Adamis, Anthony P ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CHIMERIC PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CELL PROTECTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; ENDOTHELIUM LESION; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ADHERENCE; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA BLOOD VESSEL; TISSUE LEVEL; VIRAL GENE THERAPY;

EID: 0036095059     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61115-7     Document Type: Article

References (41)

1. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition
2. Leukocyte-mediated endothelial cell injury and death in the diabetic retina
3. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid
4. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy
5. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
6. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors
7. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway
8. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway
9. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
10. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
11. Angiopoietin-1 protects the adult vasculature against plasma leakage
12. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
13. Selective expression of angiopoietin 1 and 2 in mesenchymal cells surrounding veins and arteries of the avian embryo
14. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization
15. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat
16. Comparison of VEGF, VEGF-B, VEGF-C Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
17. A simplified method for growth of human microvascular endothelial cells results in decreased senescence and continued responsiveness to cytokines and growth factors
18. The binding of T-1824 and structurally related diazo dyes by plasma proteins
19. Sensitive blood-retinal barrier breakdown quantitation using Evans blue
20. A Wilcoxon-type test for trend
21. Use of ranks in one-criterion variance analysis
22. The incidence of vision loss in a diabetic population
23. Vascular endothelial growth factor-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)
24. VEGF increases retinal vascular ICAM-1 expression in vivo
25. Vascular abnormalities in diabetes and their treatment
26. Response of capillary cell death to animoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia
27. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy
28. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate
29. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
30. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways
31. Endothelial gaps as sites for plasma leakage in inflammation
32. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression
33. Retinal VEGF induces ICAM-1 and eNOS expression and initiates early diabetic retinal leukocyte adhesion
34. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells
35. ICAM-1-induced expression of proinflammatory cytokines in astrocytes: Involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways
36. Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor-kappaB-independent mechanism
37. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
38. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Spl sites in cardiac myocytes
39. NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1 mRNA and surface expression
40. No modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R